Recombinant allergens for specific immunotherapy

Journal of Allergy and Clinical Immunology

Volumn 127, Issue 4, 2011, Pages 865-872

  Cromwell, Oliver ^a   Häfner, Dietrich ^a   Nandy, Andreas ^a  

^a Allergopharma Joachim Ganzer KG   (Germany)

Author keywords

allergen immunotherapy; allergen vaccines; hypoallergenic variants; personalized immunotherapy; Recombinant allergen; subcutaneous immunotherapy; sublingual immunotherapy

Indexed keywords

CAT ALLERGEN; CYTOKINE; FOOD ALLERGEN; GRASS POLLEN ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; PEANUT ANTIGEN; POLLEN ANTIGEN; RECOMBINANT ALLERGEN; RECOMBINANT BIRCH POLLEN ANTIGEN; RECOMBINANT DNA; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALLERGENICITY; ARTICLE; ASTHMA; BIRCH POLLEN; CAT; CLINICAL TRIAL (TOPIC); DRUG DOSE INCREASE; DRUG MECHANISM; EAR PRURITUS; FRAGMENTATION REACTION; GENE MUTATION; GENETIC ENGINEERING; GRASS POLLEN; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; NONHUMAN; OLIGOMERIZATION; PHARYNX DISEASE; PHARYNX EDEMA; POLLEN; PRIORITY JOURNAL; PRURITUS; RHINITIS; RHINOCONJUNCTIVITIS; RISK ASSESSMENT; SENSITIZATION; SITE DIRECTED MUTAGENESIS; SKIN TEST; TH2 CELL;

ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; INDIVIDUALIZED MEDICINE; RECOMBINANT PROTEINS;

EID: 79953650923     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2011.01.047     Document Type: Article

References (55)

1. K.S.Y. Fang, M. Vitale, P. Fehlner, and T.P. King cDNA cloning and primary structure of a white face hornet venom, allergen V Proc Natl Acad Sci U S A 85 1988 895 899 (Pubitemid 18073934)
2. H. Breiteneder, W. Hassfeld, K. Pettenburger, E. Jarolim, M. Breitenbach, and H. Rumpold Isolation and characterization of messenger RNA from male inflorescences and pollen of the white birch (Betula verrucosa) Int Arch Allergy Appl Immunol 87 1988 19 24
3. H. Breiteneder, K. Pettenburger, A. Bito, D. Kraft, H. Rumpold, and O. Scheiner The gene coding for the major birch allergen, Bet v I, is highly homologous to a pea disease resistance response gene EMBO J 8 1989 1935 1938 (Pubitemid 19273517)
4. K.Y. Chua, G.A. Stewart, W.R. Thomas, R.J. Simpson, R.J. Dilworth, and T.M. Plozza Sequence analysis of cDNA coding for a major house dust mite allergen Der p I J Exp Med 167 1988 175 182 (Pubitemid 18093701)
5. Guideline on allergen products: production and quality issues 2008 European Medicines Agency (EMA), Committee for Medicinal Products of Human Use (CHMP) London Publication EMEA/CHMP/BWP/304831/2007
6. K. Andersson, and J. Lidholm Characteristics and immunobiology of grass pollen allergens Int Arch Allergy Immunol 130 2003 87 107 (Pubitemid 36351233)
7. A. Mari When does a protein become an allergen? Searching for a dynamic definition based on most advanced technology tools Clin Exp Allergy 38 2008 1089 1094
8. M. Wallner, M. Himly, A. Neubauer, A. Erler, M. Hauser, and C. Asam The influence of recombinant production on the immunologic behavior of birch pollen isoallergens PLoS One 4 2009 e8457
9. R. Suck, T. Kamionka, B. Schaffer, R. Wahl, A. Nandy, and B. Weber Bacterially expressed and optimized recombinant Phl p 1 is immunobiochemically equivalent to natural Phl p 1 Biochim Biophys Acta 1764 2006 1701 1709 (Pubitemid 46053863)
10. O. Cromwell, H. Fiebig, R. Suck, H. Kahlert, A. Nandy, and J. Kettner Strategies for recombinant allergen vaccines and fruitful results from first clinical studies Immunol Allergy Clin North Am 26 2006 261 281
11. M. Jutel, L. Jaeger, R. Suck, H. Meyer, H. Fiebig, and O. Cromwell Allergen-specific immunotherapy with recombinant grass pollen allergens J Allergy Clin Immunol 116 2005 608 613 (Pubitemid 41267135)
12. R. Suck, A. Petersen, S. Hagen, O. Cromwell, W. Becker, and H. Fiebig Complemetary DNA cloning and expression of a newly recognized high mass allergen Phl p 13 from timothy grass pollen (Phleum pratense) Clin Exp Allergy 30 2000 324 332 (Pubitemid 30167247)
13. A. Hénaut, and A. Danchin F. Neidhardt, R. Curtiss III J. Ingraham, E. Lin, B. Low, B. Magasanik, Escherichia coli and Salmonella typhimurium cellular and molecular biology Vol. 2 1996 American Society for Microbiology Washington (DC) 2047 2066
14. M. Larché, C.A. Akdis, and R. Valenta Immunological mechanisms of allergen-specific immunotherapy Nat Rev Immunol 6 2006 761 771 (Pubitemid 44453462)
15. F. Ferreira, P. Briza, D. Infuhr, G. Schmidt, M. Wallner, and N. Wopfner Modified recombinant allergens for safer immunotherapy Inflamm Allergy Drug Targets 5 2006 5 14 (Pubitemid 43796677)
16. O. Cromwell Engineering allergy vaccines: approaches towards engineered allergy vaccines R. Pawankar, S.T. Holgate, L.J. Rosenwasser, Allergy frontiers: future perspectives 2010 Springer Berlin 31 47
17. T. Thalhamer, H. Dobias, T. Stepanoska, M. Proll, H. Stutz, and O. Dissertori Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening J Allergy Clin Immunol 125 2010 926 934
18. M. Wald, H. Kahlert, B. Weber, D. Jankovic, W. Keller, and O. Cromwell Generation of a low immunoglobulin E-binding mutant of the timothy grass pollen major allergen Phl p 5a Clin Exp Allergy 37 2007 441 450 (Pubitemid 46393245)
19. H. Kahlert, R. Suck, B. Weber, A. Nandy, M. Wald, and W. Keller Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy Int Arch Allergy Immunol 145 2008 193 206 (Pubitemid 351301311)
20. B. Linhart, N. Mothes-Luksch, S. Vrtala, M. Kneidinger, P. Valent, and R. Valenta A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6 Biol Chem 389 2008 925 933
21. M. van Hage-Hamsten, M. Kronqvist, O. Zetterström, E. Johansson, V. Niederberger, and S. Vrtala Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season J Allergy Clin Immunol 104 1999 969 977 (Pubitemid 29532117)
22. G. Schramm, H. Kahlert, R. Suck, B. Weber, H.T. Stüwe, and W.D. Müller "Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity J Immunol 162 1999 2406 2414 (Pubitemid 29288869)
23. I. Swoboda, A. Bugajska-Schretter, B. Linhart, P. Verdino, W. Keller, and U. Schulmeister A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy J Immunol 178 2007 6290 6296 (Pubitemid 46717412)
24. K. Westritschnig, B. Linhart, M. Focke-Tejkl, T. Pavkov, W. Keller, and T. Ball A hypoallergenic vaccine obtained by tail-to-head restructuring of timothy grass pollen profilin, Phl p 12, for the treatment of cross-sensitization to profilin J Immunol 179 2007 7624 7634
25. FAST: food allergy specific therapy. Available at: www.allergome.org: 8080/fast/index.jsp. Accessed February 15, 2011.
26. T. Saarne, L. Kaiser, H. Gronlund, O. Rasool, G. Gafvelin, and M. Hage-Hamsten Rational design of hypoallergens applied to the major cat allergen Fel d 1 Clin Exp Allergy 35 2005 657 663 (Pubitemid 40769292)
27. T. Saarne, T. Neimert-Andersson, H. Grönlund, M. Jutel, G. Gafvelin, and M. van Hage Treatment with a Fel d 1 hypoallergen reduces allergic responses in a mouse model for cat allergy Allergy 66 2011 255 263
28. P. Moingeon Sublingual immunotherapy: from biological extracts to recombinant allergens Allergy 61 suppl 81 2006 15 19
29. J.P. Allam, N. Novak, C. Fuchs, S. Asen, S. Berge, and T. Appel Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression J Allergy Clin Immunol 112 2003 141 148 (Pubitemid 36819819)
30. P. Moingeon, T. Batard, R. Fadel, F. Frati, J. Sieber, and L. Overtvelt Immune mechanisms of allergen-specific sublingual immunotherapy Allergy 61 2006 151 165 (Pubitemid 43381824)
31. G. Mistrello, O. Brenna, D. Roncarolo, D. Zanoni, and M. Gentili Monomeric chemically modified allergens: immunologic and physicochemical characterization Allergy 51 1996 8 15 (Pubitemid 26104694)
32. G. Passalacqua, M. Pasquali, R. Ariano, C. Lombardi, A. Giardini, and I. Baiardini Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites Allergy 61 2006 849 854 (Pubitemid 43893986)
33. G. Pauli, T.H. Larsen, S. Rak, F. Horak, E. Pastorello, and R. Valenta Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis J Allergy Clin Immunol 122 2008 951 960
34. C. Suphioglu What are the important allergens in grass pollen that are linked to human allergic disease? Clin Exp Allergy 30 2000 1335 1341
35. R. Asero, B. Weber, G. Mistrello, S. Amato, E. Madonini, and O. Cromwell Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: analysis of the allergenic differences between short and giant ragweed J Allergy Clin Immunol 116 2005 1036 1041 (Pubitemid 41571784)
36. R. Moverare, L. Elfman, E. Vesterinen, T. Metso, and T. Haahtela Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System Allergy 57 2002 423 430 (Pubitemid 34442156)
37. A. Joetham, K. Takeda, M. Okamoto, C. Taube, H. Matsuda, and A. Dakhama Antigen specificity is not required for modulation of lung allergic responses by naturally occurring regulatory T cells J Immunol 183 2009 1821 1827
38. A. Des Roches, L. Paradis, J.L. Menardo, S. Bouges, J.P. Daurés, and J. Bousquet Immunotherapy with a standardized Dermatophagoides pteronyssinus extract: VI. Specific immunotherapy prevents the onset of new sensitizations in children J Allergy Clin Immunol 99 1997 450 453 (Pubitemid 27173080)
39. S. Vrtala, K. Hirtenlehner, M. Susani, M. Akdis, F. Kussebi, and C.A. Akdis Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1 FASEB J 15 2001 2045 2047
40. G. Pauli, A. Purohit, J.P. Oster, F. De Blay, S. Vrtala, and V. Niederberger Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population Clin Exp Allergy 30 2000 1076 1084 (Pubitemid 30619760)
41. H. Kahlert, B. Weber, O. Cromwell, and H. Fiebig Evaluation of the allergenicity of hypoallergenic recombinant derivatives of Bet v. 1 using basophil activation vy CD203c expression measurement G. Marone, Clinical immunology and allergy in medicine 2003 JGC Editions Naples 735 740
42. V. Niederberger, F. Horak, S. Vrtala, S. Spitzauer, M.-T. Krauth, and P. Valent Vaccination with genetically engineered allergens prevents progression of allergic disease Proc Nat Acad Sci U S A 101 suppl 2 2004 14677 14682 (Pubitemid 39346742)
43. A. Purohit, V. Niederberger, M. Kronqvist, F. Horak, R. Gronneberg, and R. Suck Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives Clin Exp Allergy 38 2008 1514 1525
44. G. Gafvelin, S. Thunberg, M. Kronqvist, H. Grönlund, R. Grönneberg, and M. Troye-Blomberg Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1 Int Arch Allergy Immunol 138 2005 59 66 (Pubitemid 41291566)
45. A. Narkus, F. Kniest, A. Menzel, H. Meyer, and V. Sprung Clinical trials with recombinant allergens - three perspectives: industry. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankfurt A M 96 2009 270 278
46. J. Kettner, H. Meyer, A. Narkus, O. Cromwell, and K. Jost Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV is clinically efficacious - results of a phase III study [abstract] Allergy 62 suppl 83 2007 33
47. L. Winther, L.K. Poulsen, B. Robin, M. Melac, and H. Malling Safety and tolerability of recombinant Bet v. 1 (rBet v 1) tablets in sublingual immunotherapy (SLIT) [abstract] J Allergy Clin Immunol 123 suppl 2009 S215
48. S. Rak, F. De Blay, M. Worm, B. Robin, M. Mélac, and H. Malling Efficacy and safety of recombinant Bet v 1 (rBet v 1) tablets in sublingual immunotherapy [abstract] Allergy 65 suppl 65 2010 4
49. R. Crameri, S. Fluckiger, I. Daigle, T. Kundig, and C. Rhyner Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines Allergy 62 2007 197 206 (Pubitemid 46090303)
50. G. Senti, D. Kuster, J. Martinez-Gomez, M. Steiner, H. Rose, and R. Crameri Intralymphatic allergen specific immunotherapy using modified recombinant allergen targeting the MHC class II pathway: a double-blind placebo-controlled clinical trial in cat dander allergic patients [abstract] Allergy 64 suppl 90 2009 74
51. N. Johansen, R.W. Weber, H. Ipsen, D. Barber, L. Broge, and C. Hejl Extensive IgE cross-reactivity towards the Pooideae grasses substantiated for a large number of grass-pollen-sensitized subjects Int Arch Allergy Immunol 150 2009 325 334
52. E.F. Juniper, and G.H. Guyatt Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis Clin Exp Allergy 21 1991 77 83
53. R. Valenta, J. Lidholm, V. Niederberger, B. Hayek, D. Kraft, and H. Gronlund The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT) Clin Exp Allergy 29 1999 896 904 (Pubitemid 29317799)
54. S. Kaul, L. Englert, S. May, and S. Vieths Regulatory aspects of specific immunotherapy in Europe Curr Opin Allergy Clin Immunol 10 2010 594 602
55. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases 2008 European Medicines Agency (EMA), Committee for Medicinal Products of Human Use (CHMP) London Publication EMEA/CHMP/EWP/18504/2006